Mutagenic epoxide impurities discovered in two new beta-adrenergic blocking agents

Area of Science:

• Pharmacology
• Toxicology
• Medicinal Chemistry

Background:

• Beta-adrenergic blocking agents are widely used medications.
• Drug purity is critical for patient safety and therapeutic efficacy.
• Mutagenic impurities in pharmaceuticals can pose significant health risks.

Purpose of the Study:

• To assess the purity of newly synthesized beta-adrenergic blocking drugs, Zami 1305 and Zami 1327.
• To identify any potential mutagenic contaminants in these drug preparations.
• To evaluate the potential health implications of identified impurities.

Main Methods:

• Synthesis and purification of Zami 1305 and Zami 1327.
• Utilized the Salmonella/microsome mutagenicity test (Ames test) with bacterial strains TA 100 and TA 1535.
• Chemical analysis to identify the nature of the impurities.

Main Results:

• Preparations of Zami 1305 and Zami 1327 were contaminated with expoxides.
• These epoxide impurities demonstrated direct mutagenic activity in the Salmonella/microsome mutagenicity test.
• The identified impurities were epoxide compounds.

Conclusions:

• The presence of mutagenic expoxide impurities in Zami 1305 and Zami 1327 is a significant concern.
• Given the established correlation between mutagenicity and carcinogenicity, these contaminated drugs may represent a health hazard.
• Further investigation and stringent quality control measures are warranted for these beta-adrenergic blocking agents.